Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Zacks
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Zacks
More News
Bruker Gains 66.3% in a Year: What's Driving the Rally?
BRKR shares surge 66.3% in a year, fueled by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.
Zacks
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.
Zacks
Here's Why You Should Retain WAT Stock in Your Portfolio for Now
Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.
Zacks
BDX Expands U.S. Manufacturing With $19B Healthcare Investment
BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.
Zacks
Reasons to Add Globus Medical Stock to Your Portfolio Now
GMED gains musculoskeletal share on strong spine and trauma growth, while product innovation and a debt-free balance sheet support its appeal.
Zacks
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's broad product portfolio, global expansion and strategic M&A support growth, while tariffs and China pressures remain key risks.
Zacks
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal
GEHC's $945M SOFIE Biosciences deal will expand its U.S. PET radiopharmaceutical footprint and boost exposure to precision care growth.
Zacks
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
Zacks
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.